The impact of immunotherapy on disease progression and survival remains uncertain, but biomarker selection may be the future
Findings from the SANO trial also reported clinically complete responses after neoadjuvant chemoradiotherapy
Efficacy of PD-1 inhibitors in this setting reflects that reported in triple-negative breast cancer and is confirmed by long-term data presented at the ESMO Congress
Recently presented results suggest that a subset of patients with early stage rectal cancer could skip pre-operative radiotherapy, thus raising some questions about the standard of care
Regulatory, practical and economic challenges are associated with implementing this personalised treatment on a larger scale, thus currently limiting its availability and accessibility to patients
At the ESMO Congress 2023, our mission with the newspaper articles and expert opinions is to disseminate clear information from the studies presented and help understand their potential impact on cancer care
While increasing evidence from studies support pregnancy after cancer treatment, data gaps persist, particularly regarding the impact of novel therapies on fertility
Constant advocacy by patient groups at all levels is needed to help people with cancer navigate the healthcare system ensuring access to novel medicines which is still a major issue in different countries
ESMO is at the forefront of digital oncology, with some initiatives that support oncologists navigating the emerging opportunities in the field of real-world data research
ESMO Women for Oncology Awardee Prof. Georgina Long talks of addressing gender bias in oncology
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.